Evaluation of Quality of Life, Anxiety, and Depression in Patients with Primary Axillary Hyperhidrosis Undergoing Treatment with a Microwave Device: One-year Follow-up
DOI:
https://doi.org/10.2340/actadv.v104.40543Keywords:
axillary, hyperhidrosis, microwave, quality of life, anxietyAbstract
Hyperhidrosis is associated with social and emotional stress, affecting quality of life. Microwave energy technology treats primary axillary hyperhidrosis by thermolysis of sweat glands. The successful reduction of sweating in patients with primary axillary hyperhidrosis after microwave treatment has been studied, but there is limited evidence on the psychological and long-term effects. This study examined patient- reported outcome measures including depression and anxiety in patients with primary axillary hyperhidrosis and the effect of microwave therapy on these parameters. Patients received 1 or 2 microwave-based treatments, within 3-month intervals. All patients were finally examined at approximately 1 year after the first treatment using the Hyperhidrosis Disease Severity Scale, Hyperhidrosis Quality of Life©, Dermatology Life Quality Index, and Hospital Anxiety and Depression Scale©. A total of 103 individuals with primary axillary hyperhidrosis were included in the study, with a Hyperhidrosis Disease Severity Scale score of 3 or 4. Statistically significant improvement in quality of life, anxiety, and depression scores were observed at 1-year follow-up. The primary endpoint, Hyperhidrosis Disease Severity Scale of 2 or less 1 year after the first treatment, was achieved by 88.2% of patients. No serious adverse side effects were observed.
Downloads
References
Henning MAS, Reguant R, Jorgensen IF, Andersen RK, Ibler KS, Pedersen OB, et al. The temporal association of hyperhidrosis and its comorbidities: a nationwide hospital-based cohort study. J Eur Acad Dermatol Venereol 2022; 36: 2504-2511.
https://doi.org/10.1111/jdv.18351 DOI: https://doi.org/10.1111/jdv.18351
Ricchetti-Masterson K, Symons JM, Aldridge M, Patel A, Maskell J, Logie J, et al. Epidemiology of hyperhidrosis in 2 population-based health care databases. J Am Acad Dermatol 2018; 78: 358-362.
https://doi.org/10.1016/j.jaad.2017.10.004 DOI: https://doi.org/10.1016/j.jaad.2017.10.004
Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and characteristics of hyperhidrosis in Sweden: a cross-sectional study in the general population. Dermatology 2016; 232: 586-591.
https://doi.org/10.1159/000448032 DOI: https://doi.org/10.1159/000448032
Parashar K, Adlam T, Potts G. The impact of hyperhidrosis on quality of life: a review of the literature. Am J Clin Dermatol 2023; 24: 187-198.
https://doi.org/10.1007/s40257-022-00743-7 DOI: https://doi.org/10.1007/s40257-022-00743-7
Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001; 8: 247-252.
https://doi.org/10.1046/j.1468-1331.2001.00207.x DOI: https://doi.org/10.1046/j.1468-1331.2001.00207.x
Shayesteh A, Janlert U, Nylander E. Hyperhidrosis - sweating sites matter: quality of life in primary hyperhidrosis according to the sweating sites measured by SF-36. Dermatology 2017; 233: 441-445.
https://doi.org/10.1159/000486713 DOI: https://doi.org/10.1159/000486713
Henning M, Ibler K, Loft I, Jennum P, Didriksen M, Ullum H, et al. Hyperhidrosis is associated with sleep disturbances, daytime tiredness, stress, and depression: a retrospective cohort study from the Danish Blood Donor Study. J Am Acad Dermatol 2023; 88: 196-197.
https://doi.org/10.1016/j.jaad.2022.03.063 DOI: https://doi.org/10.1016/j.jaad.2022.03.063
Klein SZ, Hull M, Gillard KK, Peterson-Brandt J. Treatment patterns, depression, and anxiety among US patients diagnosed with hyperhidrosis: a retrospective cohort study. Dermatol Ther (Heidelb) 2020; 10: 1299-1314.
https://doi.org/10.1007/s13555-020-00439-y DOI: https://doi.org/10.1007/s13555-020-00439-y
Shayesteh A, Gerdsdorff F, Persson M, Brulin C, Nylander E. Navigating in the fog: facing delays, rejection and ignorance when seeking help for primary hyperhidrosis. Int J Qual Stud Health Well-being 2021; 16: 1930642.
https://doi.org/10.1080/17482631.2021.1930642 DOI: https://doi.org/10.1080/17482631.2021.1930642
Naeini FF, Saffaei A, Pourazizi M, Abtahi-Naeini B. Histopathological evidence of efficacy of microneedle radiofrequency for treatment of axillary hyperhidrosis. Indian J Dermatol Venereol Leprol 2015; 81: 288-290.
https://doi.org/10.4103/0378-6323.154789 DOI: https://doi.org/10.4103/0378-6323.154789
Zhang Y, Gong YY, Tang YL, Bai YS, Yang K, Chen HY, et al. Clinical efficacy of microwave in the treatment of axillary osmidrosis and primary hyperhidrosis. Dermatol Ther 2022; 35: e15657.
https://doi.org/10.1111/dth.15657 DOI: https://doi.org/10.1111/dth.15657
Lupin M, Hong HC, O'Shaughnessy KF. Long-term efficacy and quality of life assessment for treatment of axillary hyperhidrosis with a microwave device. Dermatol Surg 2014; 40: 805-807.
Johnson JE, O'Shaughnessy KF, Kim S. Microwave thermolysis of sweat glands. Lasers Surg Med 2012; 44: 20-25.
https://doi.org/10.1002/lsm.21142 DOI: https://doi.org/10.1002/lsm.21142
Abtahi-Naeini B, Naeini FF, Saffaei A, Behfar S, Pourazizi M, Mirmohammadkhani M, et al. Treatment of primary axillary hyperhidrosis by fractional microneedle radiofrequency: is it still effective after long-term follow-up? Indian J Dermatol 2016; 61: 234.
https://doi.org/10.4103/0019-5154.177789 DOI: https://doi.org/10.4103/0019-5154.177789
Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004; 51: 274-286.
https://doi.org/10.1016/j.jaad.2003.12.029 DOI: https://doi.org/10.1016/j.jaad.2003.12.029
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27-33.
https://doi.org/10.1159/000365390 DOI: https://doi.org/10.1159/000365390
Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes 2017; 15: 121.
https://doi.org/10.1186/s12955-017-0693-x DOI: https://doi.org/10.1186/s12955-017-0693-x
Gabes M, Jourdan C, Schramm K, Masur C, Abels C, Kamudoni P, et al. Hyperhidrosis Quality of Life Index (HidroQoL(c)): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial. Br J Dermatol 2021; 184: 473-481.
https://doi.org/10.1111/bjd.19300 DOI: https://doi.org/10.1111/bjd.19300
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
https://doi.org/10.1111/j.1600-0447.1983.tb09716.x DOI: https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
Stern AF. The hospital anxiety and depression scale. Occup Med (Lond) 2014; 64: 393-394.
https://doi.org/10.1093/occmed/kqu024 DOI: https://doi.org/10.1093/occmed/kqu024
S G. Anesthesia delivery with syringe adapter for miraDry® (modified technique). [Online] Available from https://www.gerrishmedesthetics.com/services/miradry/miradry-fresh-procedure-developed-by-dr-scott-gerrish/
Parrish C, Waldbaum B, Coleman D, Blevins C, Rodgers K, Lee B, et al. Microwave thermolysis reduces generalized and social anxiety in young adults with axillary hyperhidrosis. Lasers Surg Med 2020; 52: 842-847.
https://doi.org/10.1002/lsm.23229 DOI: https://doi.org/10.1002/lsm.23229
Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg 2012; 38: 728-735.
https://doi.org/10.1111/j.1524-4725.2012.02375.x DOI: https://doi.org/10.1111/j.1524-4725.2012.02375.x
Tan Y, Huang W, Liu J, Duan Z, He X, Li Q, et al. The application of microwaves in axillary hyperhidrosis: curative effect observation of a pathological examination over 1 year. J Cosmet Dermatol 2024; 23: 134-140.
https://doi.org/10.1111/jocd.15909 DOI: https://doi.org/10.1111/jocd.15909
Wang J, Wu X, Lai W, Long E, Zhang X, Li W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open 2017; 7: e017173.
https://doi.org/10.1136/bmjopen-2017-017173 DOI: https://doi.org/10.1136/bmjopen-2017-017173
Tiller JW. Depression and anxiety. Med J Aust 2013; 199: S28-31.
https://doi.org/10.5694/mjao12.10628 DOI: https://doi.org/10.5694/mjao12.10628
Braganca GM, Lima SO, Pinto Neto AF, Marques LM, Melo EV, Reis FP. Evaluation of anxiety and depression prevalence in patients with primary severe hyperhidrosis. An Bras Dermatol 2014; 89: 230-235.
https://doi.org/10.1590/abd1806-4841.20142189 DOI: https://doi.org/10.1590/abd1806-4841.20142189
Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol 2016; 75: 1126-1133.
https://doi.org/10.1016/j.jaad.2016.07.001 DOI: https://doi.org/10.1016/j.jaad.2016.07.001
Kristensen JK, Moller S, Vestergaard DG, Horsten HH, Swartling C, Bygum A. Anxiety and depression in primary hyperhidrosis: an observational study of 95 consecutive Swedish outpatients. Acta Derm Venereol 2020; 100: adv00240.
https://doi.org/10.2340/00015555-3598 DOI: https://doi.org/10.2340/00015555-3598
Shayesteh A, Boman J, Janlert U, Brulin C, Nylander E. Primary hyperhidrosis: implications on symptoms, daily life, health and alcohol consumption when treated with botulinum toxin. J Dermatol 2016; 43: 928-933.
https://doi.org/10.1111/1346-8138.13291 DOI: https://doi.org/10.1111/1346-8138.13291
Ruchinskas RA, Narayan RK, Meagher RJ, Furukawa S. The relationship of psychopathology and hyperhidrosis. Br J Dermatol 2002; 147: 733-735.
https://doi.org/10.1046/j.1365-2133.2002.04857.x DOI: https://doi.org/10.1046/j.1365-2133.2002.04857.x
Schut C, Dalgard FJ, Bewley A, Evers AWM, Gieler U, Lien L, et al. Body dysmorphia in common skin diseases: results of an observational, cross-sectional multicentre study among dermatological outpatients in 17 European countries. Br J Dermatol 2022; 187: 115-125.
https://doi.org/10.1111/bjd.21021 DOI: https://doi.org/10.1111/bjd.21021
Shayesteh AB, Boman J, Nylander E. Impostor phenomenon is a common feature among individuals with primary hyperhidrosis. SAGE Open Med 2024; Jan 27: 12.
https://doi.org/10.1177/20503121231220828 DOI: https://doi.org/10.1177/20503121231220828
Albucker SJ, Lipner SR. Microwave energy devices for hyperhidrosis are associated with infections, neurologic symptoms, and burns in a retrospective analysis of the Manufacturer and User Facility Device Experience database 2013-2022. J Am Acad Dermatol 2023; 89: 820-822.
https://doi.org/10.1016/j.jaad.2023.06.005 DOI: https://doi.org/10.1016/j.jaad.2023.06.005
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Maria Pissa, Rasha Hashem, Alexander Shayesteh, Sarah Wrisley, Emanuela Micu
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
